A blood-based microRNA assay integrated CA19-9 to form a composite score called PANXEON that demonstrated improved sensitivity for detecting early-stage pancreatic ductal adenocarcinoma. Read more ➡️ hubs.li/Q04ygSPl0 #pancsm #pancreaticcancer #oncology #cancer

From second cancers after CAR T, to an oral NEK7 inhibitor in lower-risk MDS, and MRD-guided CLL care, experts from @MSKCancerCenter, @MoffittNews, and @unmc unpack key #SOHO2026 takeaways. Watch: piped.video/dEdLxXGvBUQ #Lymphoma #MDS #CLL

🧐 How can health systems foster psychedelic literacy in oncology? Jason Konner, MD, of Psychedelic Oncology, highlights the importance of expanding provider education to better guide post-journey patient conversations. He emphasized moving beyond standard clinical checklists to connect with the spiritual and emotional dimensions of care. Ultimately, he asserted these discussions open deeper portals of insight into the whole patient. #OncTwitter #PsychedelicOncology #CancerCare

🗓️ Mark your calendars and get your Instagram accounts ready because @AlexisNarvaezMD will be taking over our account during #ASTRO2026. 📍Instagram: cancernetwrk 📅 Monday September 28th ⏰ Starting 7 am ET

Health Canada has issued a Notice of Compliance for epcoritamab with lenalidomide and rituximab in R/R grade 1, 2, or 3a follicular lymphoma that's received at least 1 prior line of systemic therapy. hubs.li/Q04ygPlD0 #lymsm #lymphoma #oncology #cancer

The FDA has granted platform technology designation to the AdenoVerse immunotherapeutic platform, to be used across a range of indications, including HPV-positive malignancies such as HNSCC, cervical, anal, vulvar, and vaginal cancers, among others. hubs.li/Q04y9JPQ0 #hncsm #gynscm #gicsm #oncology #cancer

The FDA approval of belzutifan plus lenvatinib in advanced clear cell RCC following progression on a PD-1 or PD-L1 inhibitor was based on data from the LITESPARK-011 trial. hubs.li/Q04ygzPK0 #RCC #kcsm #oncology #cancer

The Ministry of Health, Labour and Welfare in Japan has approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous administration across all indications approved in Japan for intravenous pembrolizumab. hubs.li/Q04y9J1Q0 #lcsm #oncology #cancer

As CAR-T moves earlier in #MultipleMyeloma, the question isn’t just who should receive it - but when. Great discussion with @SurbhiSidanaMD & Doris Hansen on sequencing CAR-T and bispecifics, early referral, and building true shared care between CAR-T centers and the community. #mmsm @CancerNetwrk cancernetwork.com/view/optim…

More myeloma data still shaping treatment decisions: BCMA CAR T-cell therapy showed an OS edge over teclistamab, and the CELMoD mezigdomide cut the risk of progression or death by 52% vs Kd in the phase 3 SUCCESSOR-2 trial. Read here: hubs.li/Q04ycF4P0

Rusfertide is now considered a category 1 treatment option for low- and high-risk polycythemia vera by the NCCN. It is the only treatment that is category 1 across both risk groups. hubs.li/Q04y4YZN0 #HemOnc #PolycythemiaVera #oncology #cancer

The FDA MCGP advisory committee has voted in favor of the Galleri multicancer early detection test for all 3 questions posed by the agency. hubs.li/Q04y9-hR0 #oncology #cancer #MCED | @FDA

The @FDA has approved lirafugratinib (Lyrfigtu), an investigational oral FGFR2 inhibitor, as a treatment for patients with previously treated unresctable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 gene fusion or other rearrangement. For more information 👉 cancernetwork.com/view/fda-g… #CCA #CCF #Oncology | @FDA

🔬 Phase 1 trials are the foundation of clinical research! We teamed up with @cure_today to interview Peter Forsyth, MD, and Heather Curley, a doctor and a patient with breast cancer from the same phase 1 trial! 📝 Find the interview with Dr. Forsyth on our website, and the interview with Heather on Cure's! #bcsm #breastcancer #CNS #oncology

TG4050 demonstrated encouraging clinical activity as adjuvant monotherapy in patients with resected, locally advanced, HPV-negative head and neck squamous cell carcinoma. Learn more about the Modified Vaccinia Ankara viral vector–based individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted tumor neoantigens: hubs.li/Q04y4VLG0 #hncsm #oncology #cancer

Quad therapy in NDMM isn't one-size-fits-all. Access, patient preference, and multidisciplinary coordination all shape the treatment path. Watch @DrOlaLandgren & @NoopurRajeMD discuss in the this Between The Lines episode. Watch here: hubs.li/Q04rZT1R0

A new study published in npj Precision Oncology demonstrates the diagnostic power of an AI-driven multi-dimensional cfDNA fragmentomics approach for the early detection and risk stratification of head and neck squamous cell carcinoma. 👉 The ensemble machine learning model integrates focal copy number variations, fragment size profiles, and genome-wide methylation patterns. 👉 The model achieved validation AUCs up to 0.966 with over 78% sensitivity at 95% specificity across cohorts. 👉 Higher prediction scores independently correlated with lymph node metastasis and worse overall survival, marking a major step forward in noninvasive screening. #HNSCC #LiquidBiopsy #Oncology #PrecisionMedicine #ArtificalIntelligence #CancerResearch

COA (@oncologyCOA) is warning CMS that Medicare Part B drug price negotiation could hit community oncology hard: 1️⃣ MFP-based reimbursement could replace ASP+6% starting 2028 2️⃣ Projected 39%–64% cut to oncology/hematology add-on payments 3️⃣ Risk: fewer therapies, consolidation, practice closures hubs.li/Q04x_yBV0 #oncology #COA #MedicarePartB #cancer